secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2026-08-11T20:05:17+00:00
Accession:  0001193125-26-344577
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome Q2 net loss $73.1M; FDA accepts varegacestat NDA, PDUFA April 28, 2027
-------------------------------------------------------------------------------

- FDA accepted NDA for varegacestat in desmoid tumors; PDUFA target April 28, 2027.
- Phase 3 RINGSIDE: 84% risk reduction (HR=0.16, p<0.0001); ORR 56% vs 9%.
- Cash $520.0M as of June 30, 2026; expected to fund operations into 2028.
- Q2 net loss $73.1M; R&D $59.9M, G&A $18.3M including stock comp.
- First patients dosed in Phase 1 trials of IM-1617 (June 2026) and IM-3050 (July 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/0001193125-26-344577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer